Study Detail: Ophthotech 1001
Trial Description Summary : Controlled trial for safety and efficacy of intravitreal injection of E10030 (anti-platelet derived growth factor {anti-PDGF}) given in combination with Lucentis in patients with treatment naive CNV from AMD.
Basic Trial Information
Phase: 2
Disease: Macular Degeneration (wet form)
Sponsor: Ophthotech Corp.
Protocol Number: OPH1001
Status: Enrolling
Study Duration: 24 weeks (9 visits)
Eligibility Criteria:
Inclusion Criteria
CNV is predominately classic or minimally classic
BCVA 20/63-20/200
Total lesion greater than, or equal to 5 disc areas of which 50% must be active
OCT Cirrus > 300 or Status > 250
IOP < 21
Clear ocular media for photo evaluation
Exclusion Criteria
Ophthalmic
Any prior treatment for AMD (other than vitamins/minerals)
Any prior intravitreal treatment in study eye, regardless of indication
>25% of lesion made up of scar or atrophy
>50% of lesion made up of SRH (sub retinal hemorrhage)
RAP lesions
Presence of significant PEDs
Any intraocular surgery or thermal laser within 3 months of the trial
Any prior thermal laser in the macular region for any indication
Aphakia
Any ocular or periocular infection in the past 12 weeks
General Medical
Diabetes
Severe cardiac disease
MI in past 6 months
CVA within 12 months
Major surgery within one month
Clinically significant renal or hepatic disease
Any treatment with investigational agent within one month of trial entry
The above inclusion/exclusion criteria is not complete and the study coordinator will do a complete screening.
Study Title : A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination with Lucentis in Subjects with Neovascular Age-Related Macular Degeneration
Trial Contact Information
Site: Beachwood
Study Coordinator: Diane W. @ 216/831-5700


